|
KMID : 1022820200110010001
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2020 Volume.11 No. 1 p.1 ~ p.13
|
|
|
COVID-19 and Neuroimmunological Disorders
|
|
Choi Seok-Jin
Baek Seol-Hee
Yang Ji-Won
Huh So-Young
Park Kee-Hong
Kim Sang-Beom
Kim Ko-Woon
Park Su-Yeon
Sohn Sung-Yeon
Oh Jung-Hwan
Shin Je-Young
Kim Jee-Eun
Ahn Suk-Won
|
|
|
Abstract
|
|
|
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19) emerged in December 2019. Unfortunately, the World Health Organization declared COVID-19 a pandemic on March 2020. The pulmonary manifestations of COVID-19 have been well-described, and neurological manifestations including headache, anosmia, altered consciousness, stroke, and post-infectious autoimmunity, are being increasingly recognized. Furthermore, the COVID-19 pandemic is concerning for patients with neuroimmunological disorders who are receiving immunotherapy. It is not known if immunosuppression increases the risk of SARS-CoV-2 infection or worsens infection severity. Although national and international medical societies have developed several guidelines and statements, there is no consensus on neurological immunotherapy in COVID-19 patients. In this Review, we aimed to summarize international recommendations or currently available published reports, and provide management approaches to neurological immunotherapy in the COVID-19 era.
|
|
|
KEYWORD
|
|
|
COVID-19, SARS-CoV-2, Neurology, Immunology, Immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|